WINTON GROUP Ltd reduced its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 4.0% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,096 shares of the company’s stock after selling 253 shares during the quarter. WINTON GROUP Ltd’s holdings in Establishment Labs were worth $532,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Sei Investments Co. bought a new position in shares of Establishment Labs during the 2nd quarter valued at about $657,000. Swiss National Bank bought a new position in shares of Establishment Labs during the 2nd quarter valued at about $3,651,000. Legato Capital Management LLC bought a new position in shares of Establishment Labs during the 2nd quarter valued at about $268,000. Teacher Retirement System of Texas bought a new position in shares of Establishment Labs during the 2nd quarter valued at about $213,000. Finally, GSA Capital Partners LLP increased its position in shares of Establishment Labs by 40.0% during the 2nd quarter. GSA Capital Partners LLP now owns 7,239 shares of the company’s stock valued at $632,000 after purchasing an additional 2,070 shares during the last quarter. Institutional investors and hedge funds own 60.27% of the company’s stock.
In other news, Director Dennis E. Condon sold 9,000 shares of the firm’s stock in a transaction that occurred on Friday, September 10th. The stock was sold at an average price of $73.50, for a total value of $661,500.00. Following the completion of the transaction, the director now owns 9,000 shares in the company, valued at approximately $661,500. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lisa Gersh sold 18,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 5th. The shares were sold at an average price of $70.56, for a total value of $1,270,080.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $705,600. The disclosure for this sale can be found here. Company insiders own 13.08% of the company’s stock.
Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, July 29th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.06. Establishment Labs had a negative return on equity of 29.92% and a negative net margin of 19.78%. The business had revenue of $31.99 million during the quarter, compared to analysts’ expectations of $31.50 million. Sell-side analysts predict that Establishment Labs Holdings Inc. will post -1.14 earnings per share for the current year.
ESTA has been the topic of several recent research reports. Jefferies Financial Group assumed coverage on Establishment Labs in a research report on Friday, July 30th. They set a “buy” rating and a $90.00 price objective on the stock. BTIG Research restated a “buy” rating and set a C$90.00 target price on shares of Establishment Labs in a report on Monday, August 23rd. Zacks Investment Research upgraded Establishment Labs from a “sell” rating to a “hold” rating in a report on Monday, September 6th. Finally, The Goldman Sachs Group increased their target price on Establishment Labs from $68.00 to $78.00 and gave the company a “neutral” rating in a report on Tuesday, August 3rd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Establishment Labs presently has an average rating of “Buy” and an average price target of $84.60.
Establishment Labs Company Profile
Establishment Labs Holdings, Inc is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It operates through the following geographical segments: Europe, Latin America, Asia Pacific and Middle East, and Other. The firm’s products include Motiva Implants, Motiva Flora Tissue Expander, Divina, and Puregraft.
Recommended Story: Growth Stocks
Want to see what other hedge funds are holding ESTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Establishment Labs Holdings Inc. (NASDAQ:ESTA).
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.